Introduction {#section1-2050313X20943068}
============

Endovascular intervention of iliac artery disease is less invasive than bypass surgery, does not require general anesthesia, has a high rate of technical success, and provides durable patency.^[@bibr1-2050313X20943068]^ The 2016 American College of Cardiology/American Heart Association (AHA/ACC) Guidelines on the Management of Patients with Lower Extremity Peripheral Artery Disease (PAD) state that endovascular procedures are an effective revascularization strategy for patients with lifestyle-limiting claudication and hemodynamically significant aortoiliac occlusive disease (AOID).^[@bibr2-2050313X20943068]^ The standard of care for the endovascular treatment of iliac artery disease is stenting and it provides comparable patency compared with aorto-femoral bypass surgery with a lower risk of infection and bleeding.^[@bibr3-2050313X20943068]^ However, the presence of calcification may preclude the delivery of large bore devices, as well as stent placement or optimal stent expansion that could lead to restenosis, recurrence of ischemia, and repeat revascularization. Modification of calcified plaque with orbital atherectomy (OA) may facilitate the delivery and expansion of a balloon or stent, as well as other large bore devices. Data on OA in the iliac artery are limited, but a recent analysis indicated that OA in the iliac artery is feasible with few reported angiographic complications and compared favorably with a superficial femoral artery (SFA) control group.^[@bibr4-2050313X20943068]^ Since there is a dearth of information, we present here a case series of OA utilization in the iliac artery to allow for large bore device delivery.

Case report series {#section2-2050313X20943068}
==================

The Diamondback 360 Peripheral Orbital Atherectomy System (Cardiovascular Systems, Inc. (CSI), St. Paul, MN, USA) was utilized in all 13 cases at a single center (WakeMed Heart & Vascular, WakeMed Hospital, Raleigh, NC, USA). As previously reviewed, the mechanism of the OA device has been shown to be useful in the treatment of calcified, noncompliant peripheral lesions prior to appropriate percutaneous transluminal angioplasty and adequate stent deployment if needed.^[@bibr5-2050313X20943068][@bibr6-2050313X20943068]--[@bibr7-2050313X20943068]^ As indicated in [Table 1](#table1-2050313X20943068){ref-type="table"}, the patient demographics of this case report series included elderly smokers with a high prevalence of diabetes and hypertension. These demographic risk factors are indicative of patients with severe peripheral artery disease and heavily calcified lesions.^[@bibr5-2050313X20943068]^ In addition, the OA 2.0-mm crown was the most common crown size and a consistent algorithm of low-, medium-, and then high-speed rotation was utilized in all cases ([Table 1](#table1-2050313X20943068){ref-type="table"}).

###### 

Summary of baseline demographics and lesion/procedural characteristics.

![](10.1177_2050313X20943068-table1)

  Baseline demographics                                N = 13
  ---------------------------------------------------- -----------------------------------------------------------------
  Age (years)                                          74.8 ± 10.2
  Male gender                                          9 (69)
  Diabetes                                             7 (54)
  Hyperlipidemia                                       6 (46)
  Hypertension                                         12 (92)
  Current/former smoker                                10 (77)
  Vessel/lesion characteristics                        
  Target limb(s)                                       
   Left lower extremity                                4 (30.8)
   Right lower extremity                               6 (46.2)
   Both lower extremities                              3 (23.1)
  Vessel(s) treated                                    
   Common iliac                                        5 (38.5)
   Common iliac and external iliac                     2 (15.4)
   Common iliac and common femoral                     1 (7.7)
   External iliac                                      4 (30.7)
   Left and right external iliac                       1 (7.7)
  Reference vessel diameter (mm)                       9.2 ± 0.9
  Lesion length (mm)                                   34.0 ± 10.8
  Severe calcification                                 13 (100)
  Procedural characteristics                           
  Femoral access site                                  13 (100)
  Atherectomy                                          
   Orbital atherectomy                                 13 (100)
    2.0 mm solid crown                                 12 (92.3)
    2.25 mm solid crown                                1 (7.7)
   Viper wire                                          13 (100)
   Mean total orbital atherectomy treatment time (s)   120.0 ± 37.0
   High rotational speed (120 krpm)                    13 (100)^[a](#table-fn2-2050313X20943068){ref-type="table-fn"}^
  Post atherectomy balloon angioplasty                 
   Balloon diameter (mm)                               8.8 ± 1.8
   Balloon length (mm)                                 29.2 ± 10.0
   Max balloon inflation pressure (atm)                11.3 ± 7.4
  Stent placed                                         13 (100)
   Drug eluting                                        1 (7.7)
   Bare metal                                          6 (46.2)
   Covered                                             6 (46.2)
  Stent length (mm)                                    36.4 ± 10.9

Values are n (%) or mean ± standard deviation.

All cases utilized an algorithm of escalation from low to high rotational speed.

[Figures 1](#fig1-2050313X20943068){ref-type="fig"}[](#fig2-2050313X20943068){ref-type="fig"}--[3](#fig3-2050313X20943068){ref-type="fig"} provide examples of the OA utilization in severely calcified arteries after failed balloon angioplasty. Briefly, the asterisk in [Figure 1(a)](#fig1-2050313X20943068){ref-type="fig"} indicates a flow-limiting lesion preventing delivery of a guide sheath over an iliac bifurcation despite two failed attempts to advance the sheath with balloon angioplasty. [Figure 1(b)](#fig1-2050313X20943068){ref-type="fig"} shows the angiographic image post-treatment with the OA 2.0-mm solid crown and balloon angioplasty, enabling the delivery of the guide sheath and stent placement.

![Treatment of the right common iliac to facilitate delivery of a guide sheath. \*=flow-limiting lesion](10.1177_2050313X20943068-fig1){#fig1-2050313X20943068}

![Comparison of treatment methods in the left common iliac artery. \*=proximal severely calcified stenosed target lesion; \*\*=previous under-expanded stent](10.1177_2050313X20943068-fig2){#fig2-2050313X20943068}

![Bilateral iliac intervention for the delivery of a bifurcating endograft stent in an endovascular aneurysm repair. Arrows=severely calcified stenosed target lesions; green circle=OA crown](10.1177_2050313X20943068-fig3){#fig3-2050313X20943068}

In a second case, the asterisk on a pre-treatment angiographic image ([Figure 2(a)](#fig2-2050313X20943068){ref-type="fig"}) shows a proximal severely calcified stenosed target lesion (outside/proximal to previously placed stent) that failed to respond to balloon angioplasty, while the double asterisk ([Figure 2(a)](#fig2-2050313X20943068){ref-type="fig"}) indicates a previous under-expanded stent due to failed balloon angioplasty and no treatment with OA. [Figure 2(b)](#fig2-2050313X20943068){ref-type="fig"} shows an angiographic image post-treatment of the proximal lesion (non-in-stent) with the OA 2.0-mm solid crown, balloon angioplasty, and stent placement, resulting in a fully expanded stent.

Finally, the third case ([Figure 3(a)--(g)](#fig3-2050313X20943068){ref-type="fig"}) is an example bilateral iliac OA treatment after a failed balloon angioplasty procedure, resulting in the successful placement of a large bore endovascular aneurysm repair (EVAR) endograft stent and subsequent resolution of a previously existing aortic aneurysm. Briefly, [Figure 3(a)--(b)](#fig3-2050313X20943068){ref-type="fig"} shows a baseline pre-treatment angiographic image of the aortoiliac region. Arrows indicate severely calcified stenoses of right and left common iliac arteries at the origin of the descending aorta, as well as further down into the left common iliac artery. Balloon angioplasty was attempted on these lesions, but it failed to create a large enough lumen to pass the large bore EVAR device through the aortoiliac region. Thus, the procedure escalated to OA treatment ([Figure 3(c)--(d)](#fig3-2050313X20943068){ref-type="fig"}; green circle highlights the OA 2.0-mm solid crown) of these lesions which resulted in greater lumen gain and compliance change within the aortoiliac region for the successful placement of a bifurcating EVAR endograft stent ([Figure 3(e)--(g)](#fig3-2050313X20943068){ref-type="fig"}).

Overall, the retrospective analysis of the 13 cases revealed a low procedural complication rate (0%) and a high technical success rate (100%). The procedural complication rate was defined as the composite of flow-limiting dissection, perforation, slow flow, vessel closure, spasm, embolism, and thrombosis. Technical success was assessed as angiographic luminal gain and subsequent successful delivery of large bore devices through the treatment area, as well as freedom from procedural complications. Orbital atherectomy vessel preparation of calcified iliac artery lesions resulted in adequate stent expansion and enabled delivery of large profile devices.

Discussion {#section3-2050313X20943068}
==========

Aortoiliac occlusive disease (AIOD) occurrence will likely increase as the prevalence of PAD related co-morbidities becomes more widespread; a careful examination of treatment strategies and an appreciation for calcification will be necessary. Despite the challenges of treating AIOD, it is clear that patients want and need these procedures---a randomized study showed that patients' quality of life improved after receiving endovascular treatment for AOID.^[@bibr8-2050313X20943068]^ There are many available options for the treatment of calcification in AIOD, and new treatment options will surely offer additional opportunities to combat calcium. Current recommendations support an endovascular approach for AIOD,^[@bibr9-2050313X20943068]^ but other methods are available when endovascular techniques fail. Endovascular techniques appear effective among different vascular beds and the risk/benefit themes remain. Studies have also shown endovascular treatment of aortoiliac calcific occlusive disease to be technically successful, low risk, and offer short-term success. More information is needed to fully appreciate how the presence of calcification alters the success of endovascular techniques and how it affects treatment strategies. More studies are needed to see how the presence of calcification affects restenosis rates in these larger vessels. Cost considerations will also become increasingly important as providers are required to operate under cost consignment programs. The case report series presented here provides examples of successful OA in iliac arteries that facilitated the delivery and expansion of a balloon or stent, as well as other large bore devices. One major limitation of this case series, however, is the lack of intravascular imaging (intravascular ultrasound (IVUS) or optical coherence tomography (OCT)) before and after OA to determine the precise effects of the device. Since IVUS and OCT are infrequently used during OA aortoiliac peripheral interventions, it would be of value to complete a prospective intravascular imaging study of OA treatment for AOID.

Conclusion {#section4-2050313X20943068}
==========

OA vessel preparation of calcified iliac artery lesions resulted in adequate stent expansion safely and enabled delivery of rigid/large profile devices. Larger studies are warranted to evaluate patient selection criteria, as well as long-term efficacy and safety rates of OA in iliac arteries.
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